Q1 EPS Estimate for Soleno Therapeutics Raised by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Investment analysts at HC Wainwright increased their Q1 2025 EPS estimates for shares of Soleno Therapeutics in a research note issued on Monday, March 31st. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.80) for the quarter, up from their previous forecast of ($0.83). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.76) EPS, Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.37 EPS, Q4 2026 earnings at $1.06 EPS and FY2026 earnings at $1.39 EPS.

Other equities analysts also recently issued research reports about the stock. Robert W. Baird lifted their price objective on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the stock an “outperform” rating in a report on Thursday, March 27th. Lifesci Capital raised shares of Soleno Therapeutics to a “strong-buy” rating in a report on Tuesday, February 4th. Laidlaw increased their price objective on shares of Soleno Therapeutics from $75.00 to $105.00 and gave the stock a “buy” rating in a research note on Thursday, March 27th. UBS Group set a $105.00 target price on shares of Soleno Therapeutics in a report on Thursday, March 27th. Finally, Guggenheim reiterated a “buy” rating and set a $81.00 price target (up from $70.00) on shares of Soleno Therapeutics in a research report on Friday, March 28th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Soleno Therapeutics currently has a consensus rating of “Buy” and an average price target of $99.63.

Soleno Therapeutics Trading Up 7.9 %

Shares of SLNO opened at $73.67 on Thursday. The firm has a market cap of $3.38 billion, a price-to-earnings ratio of -22.19 and a beta of -2.29. Soleno Therapeutics has a 52 week low of $36.61 and a 52 week high of $73.97. The stock has a 50 day moving average of $50.32 and a 200-day moving average of $50.50.

Soleno Therapeutics (NASDAQ:SLNO) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.41).

Institutional Investors Weigh In On Soleno Therapeutics

Several institutional investors have recently bought and sold shares of the stock. AlphaQuest LLC raised its position in shares of Soleno Therapeutics by 1,154.4% during the 4th quarter. AlphaQuest LLC now owns 715 shares of the company’s stock worth $32,000 after buying an additional 658 shares in the last quarter. US Bancorp DE acquired a new position in shares of Soleno Therapeutics during the fourth quarter valued at approximately $34,000. Avanza Fonder AB bought a new stake in Soleno Therapeutics during the fourth quarter worth approximately $76,000. Springhill Fund Asset Management HK Co Ltd acquired a new stake in Soleno Therapeutics in the fourth quarter worth approximately $81,000. Finally, Avior Wealth Management LLC acquired a new stake in Soleno Therapeutics in the fourth quarter worth approximately $89,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

Insider Buying and Selling at Soleno Therapeutics

In related news, CEO Bhatnagar Anish sold 699,095 shares of the stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the transaction, the chief executive officer now directly owns 577,076 shares of the company’s stock, valued at $39,021,879.12. This represents a 54.78 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Kristen Yen sold 2,340 shares of Soleno Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $46.18, for a total value of $108,061.20. Following the sale, the insider now directly owns 76,605 shares in the company, valued at $3,537,618.90. The trade was a 2.96 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 945,012 shares of company stock worth $64,166,842. 12.30% of the stock is owned by company insiders.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.